Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | NOS1 | P29475 | 3/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.55 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.55 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL4574651 | 0.98 | MEN1 (0.56) | MEN1KMT2ANOS1GRIN2DGRIN3B | |
| SCHEMBL9290906 | 0.98 | MEN1 (0.61) | MEN1KMT2ANOS1GRIN2DGRIN3B | |
| SCHEMBL9415798 | 0.98 | MEN1 (0.61) | MEN1KMT2ANOS1GRIN2DGRIN3B | |
| SCHEMBL9290797 | 0.93 | — | — | |
| Maleic Acid SCHEMBL5151421 | 0.86 | MEN1 (0.44) | MEN1KMT2ANOS1GRIN2DGRIN3B | |
| SCHEMBL9290971 | 0.83 | — | — | |
| SCHEMBL20779515 | 0.82 | LMNA (0.55) | MEN1KMT2ANOS1GRIN2DGRIN3B | |
| SCHEMBL9059398 | 0.82 | MEN1 (0.58) | MEN1KMT2ANOS1GRIN2DGRIN3B | |
| SCHEMBL7041301 | 0.78 | MEN1 (0.59) | MEN1KMT2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL6159793 | 0.78 | GRIN2D (0.62) | MEN1KMT2AGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008095903-A1 | NEW ADDITION SALT OF N-AMINO-N'-PENTYLGUANIDINE, THE PROCESS FOR ITS PREPARATION AND USE THEREOF FOR OBTAINING TEGASEROD | CHEMO IBÉRICA, S.A. (ES) | 2008-08-14 | — | — | WO | claimed |
| EP-1955998-A1 | New addition salt of N-amino-N'-pentylguanidine, the process for its preparation and use thereof for obtaining tegaserod | Chemo Ibérica, S.A. (ES) | 2008-08-13 | — | — | EP | claimed |
| WO-2008095903-A1 | NEW ADDITION SALT OF N-AMINO-N'-PENTYLGUANIDINE, THE PROCESS FOR ITS PREPARATION AND USE THEREOF FOR OBTAINING TEGASEROD | CHEMO IBÉRICA, S.A. (ES) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095903-A1 | NEW ADDITION SALT OF N-AMINO-N'-PENTYLGUANIDINE, THE PROCESS FOR ITS PREPARATION AND USE THEREOF FOR OBTAINING TEGASEROD | CHEMO IBÉRICA, S.A. (ES) | 2008-08-14 | — | — | WO | disclosed |
| EP-1955998-A1 | New addition salt of N-amino-N'-pentylguanidine, the process for its preparation and use thereof for obtaining tegaserod | Chemo Ibérica, S.A. (ES) | 2008-08-13 | — | — | EP | disclosed |
| EP-1955998-A1 | New addition salt of N-amino-N'-pentylguanidine, the process for its preparation and use thereof for obtaining tegaserod | Chemo Ibérica, S.A. (ES) | 2008-08-13 | — | — | EP | disclosed |
| EP-1955998-A1 | New addition salt of N-amino-N'-pentylguanidine, the process for its preparation and use thereof for obtaining tegaserod | Chemo Ibérica, S.A. (ES) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007119109-A2 | PROCESSES FOR PREPARING TEGASEROD MALEATE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDICHEM, S.A. (US) | 2007-10-25 | — | — | WO | disclosed |
| CN-101018550-A | DPP-IV inhibitors and modulation of 5-HT3And/or 5-HT4Combinations of compounds of the receptor | NOVARTIS AG (CH) | 2007-08-15 | — | — | CN | disclosed |
| US-20070112056-A1 | Stable modifications of tegaserod hydrogen maleate | NOVARTIS AG (CH) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112056-A1 | Stable modifications of tegaserod hydrogen maleate | HRH2, HRH4, HRH1 | MEN1 1131/4885KMT2A 1990/4885NOS1 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.